Year-over-year earnings per share growth for the last twelve months: Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics, Inc. (SNSE) - corporate logo

Sensei Biotherapeutics is developing the ImmunoPhage platform for targeted tumor strikes without chemical toxicity. Trials of the SNS-101 molecule are attracting patients due to its safety profile, although the FDA is strictly monitoring its efficacy. A team of leading virologists is striving for a medical breakthrough. The quarterly EPS growth rate demonstrates the financial backdrop, where the current level is 37.00.

Sensei Biotherapeutics Inc (SNSE) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 06/16/2026

Comprehensive metric breakdowns and analytics for Sensei Biotherapeutics, Inc. (SNSE)

- share price and expert price forecast:
Stock Price Sensei Biotherapeutics|SNSE - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Sensei Biotherapeutics, Inc.|SNSE - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Sensei Biotherapeutics|SNSE - Company Net Assets|Market Cap to Net Assets Ratio senseibio.com|SNSE - Company Total Assets
- debt and liquidity details:
Debt to Equity Sensei Biotherapeutics|SNSE - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity senseibio.com|SNSE - Company Cumulative Debt|Debt to Book Value Sensei Biotherapeutics|SNSE - Long-Term Indebtedness|Company Current Liabilities Sensei Biotherapeutics|Quick Ratio senseibio.com
- earnings and market multiples details:
SNSE - Final Profit|Projected Future Earnings Sensei Biotherapeutics|SNSE - Market Cap to Earnings|Future Price to Earnings Sensei Bio|SNSE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple SNSE|SNSE - Operating profit EBITDA|Earnings per share for the last twelve months Sensei Biotherapeutics|SNSE - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months senseibio.com|SNSE - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Sensei Biotherapeutics
- revenue and sales proceeds data:
SNSE - Company Gross Revenue|Projected Sales Volume senseibio.com|SNSE - Price to Sales|Price-to-Projected Revenue Ratio Sensei Biotherapeutics Inc
Comprehensive company analysis:Sensei Biotherapeutics, SNSE
Manufactured product of senseibio.com

This indicator measures the quarterly dynamics of earnings per share, allowing investors to assess capital management efficiency and cash flow sustainability. By analyzing comparable quarterly EPS growth, one can confirm the financial stability of Sensei Biotherapeutics (SNSE), which is supported by seamless biocomponent logistics that eliminate operational downtime during critical oncology testing.

Competitors of Sensei Biotherapeutics

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months januxrx.com|Year-over-year net earnings per share growth for the last 12 months arcusbio.com (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc (ZYME)|Year-over-year net earnings per share growth for the last 12 months Tango Pharma TNGX|Iovance Biotherapeutics Inc - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics Biotechnologies IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (compasstherapeutics.com) - Year-over-year earnings per share growth for the last 12 months|Replimune Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Lyell Immunopharma Inc (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma)|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immix Biopharma|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|cuebiopharma.com (CUE) - Quarterly EPS earnings growth|PDSB (PDS Biotechnology Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth sonnetbio.com|Year-over-year earnings per share growth for the last twelve months MAIA Biotechnology, Inc. (MAIA)|LIMN: Year-over-year net earnings per share trend for the last twelve months|LAVA Therapeutics - Year-over-year net earnings per share growth for the last 12 months|nextcure.com (NXTC) - Earnings per share growth in annualized terms for the last twelve months|LPTX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Intensity Therapeutics, Inc. INTS|TOVX: Quarterly EPS earnings growth|Gritstone bio Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KA|Year-over-year earnings per share growth for the last 12 months NEXI (NexImmune, Inc.)|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics Corporation (TSBX)|Year-over-year net earnings per share growth for the last 12 months Vaccinex VCNX|Year-over-year earnings per share growth for the last twelve months harpoontx.com HARP